Skip to main content
Clinical Trials/NCT03153488
NCT03153488
Active, Not Recruiting
N/A

Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment Response

Massachusetts General Hospital1 site in 1 country60 target enrollmentJuly 1, 2018

Overview

Phase
N/A
Intervention
Not specified
Conditions
Attention Deficit Hyperactivity Disorder
Sponsor
Massachusetts General Hospital
Enrollment
60
Locations
1
Primary Endpoint
ADHD Clinical Global Impressions Scale - Improvement (CGI-I)
Status
Active, Not Recruiting
Last Updated
3 years ago

Overview

Brief Summary

This is a 6-month trial in adults to find out if certain neuromarkers can predict individual treatment response to stimulant medications for Attention Deficit Hyperactivity Disorder (ADHD). Males and females, ages 18-45, will complete an MRI scan at MIT prior to beginning medication for ADHD as determined by a treating clinician outside the context of this study.

Registry
clinicaltrials.gov
Start Date
July 1, 2018
End Date
December 1, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Joseph Biederman, MD

Principal Investigator

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • Male and female adults ages 18-55
  • A diagnosis of DSM-V ADHD based on clinical assessment supported by the ADHD module of a structured diagnostic interview
  • Proficiency in English
  • Right-handed

Exclusion Criteria

  • Any contraindication for the use of a stimulant medication
  • Investigator and his/her immediate family (spouse, parent, child, grandparent, or grandchild)
  • Any contraindications for MRI examination (metallic implants, such as pacemakers, surgical aneurysm clips, or known metal fragments in the body)
  • Women who are currently pregnant or breastfeeding, as confirmed by a urine pregnancy test
  • Clinically significant abnormal baseline laboratory values, including systolic and diastolic blood pressure parameters above 140 and 90, respectively and resting heart rate outside 60-100 bpm

Outcomes

Primary Outcomes

ADHD Clinical Global Impressions Scale - Improvement (CGI-I)

Time Frame: 6 months

The Clinical Global Impression - Improvement scale (CGI-I) is a 7-point scale that requires the clinician to assess how the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.

ADHD Clinical Global Impressions Scale - Severity (CGI-S)

Time Frame: 6 months

The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment.

Secondary Outcomes

  • Connectomic Variation Prediction of Medicine Response(6 months)

Study Sites (1)

Loading locations...

Similar Trials